Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania.

Stopped Due to significant delays in receiving local regulatory approval to extend the shelf-life of the IMP.

Conditions

• Malaria,Falciparum

Interventions

• BIOLOGICAL: Pfs25-IMX313 (10ug)/Matrix-M (50ug)
• BIOLOGICAL: Pfs25-IMX313 (50ug)/Matrix-M (50ug)
• BIOLOGICAL: Pfs25-IMX313 (50ug)/Matrix-M (50ug) & Pfs25-IMX313 (10ug)/Matrix-M (50ug)

Sponsor

University of Oxford

Collaborators

• [object Object]